IW-3718

DRUG5 trials

Sponsors

Ironwood Pharmaceuticals, Inc.

Conditions

Gastroesophageal RefluxGastroesophageal Reflux DiseaseGastroesophageal Reflux Disease (GERD)Healthy Volunteers

Phase 1

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

CompletedNCT03856970

Ironwood Pharmaceuticals, Inc.Healthy Volunteers

Start: 2019-03-11End: 2019-07-03Updated: 2019-07-29

Phase 2

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

CompletedNCT02030925

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux

Start: 2014-02-28End: 2014-12-31Updated: 2016-08-01

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

CompletedNCT02637557

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux Disease

Start: 2016-03-01End: 2017-04-26Updated: 2019-10-15

Phase 3

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

TerminatedNCT03561090

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2018-06-20End: 2020-11-03Updated: 2021-08-19

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

CompletedNCT03561883

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2018-09-06End: 2020-11-06Updated: 2021-08-18

Related Papers

IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial

Gastroenterology2020-02-2146 citations

Evaluation and Validation of the Modified Reflux Symptom Questionnaire–Electronic Diary in Patients With Persistent Gastroesophageal Reflux Disease

Clinical and Translational Gastroenterology2020-01-012 citations